MetaCap

DBV Technologies S.A. (DBVT) vs Valneva (VALN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DBV Technologies S.A. (DBVT) has outperformed Valneva (VALN) over the past year, losing 34.4% versus a loss of 40.1%. Over five years, DBVT leads with a +50.3% price change compared with -91.3% for VALN. DBV Technologies S.A. is the larger company by market cap ($566.8 million vs $490.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DBVT-34.40%VALN-40.14%
+85%+17%-51%
Nov 21, 20251 yearNov 20, 2026
DBVT+47.43%VALN-89.45%
+321%+104%-112%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DBVT versus VALN key metrics
MetricDBVTVALN
Share price$9.02$5.16
Market cap$566.82M$490.86M
1-day change-4.25%-3.82%
YTD return-52.95%-41.50%
1-year return-34.40%-40.14%
5-year return+50.33%-91.34%
Forward P/E—4.34
EPS (TTM)$-3.00$-2.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.64M—
Revenue growth (YoY)+35.77%—
Net income (latest FY)$-146.95M—
Operating margin-2609.23%—
Net margin-2607.29%—
52-week high$26.19$12.18
52-week low$8.63$4.75
Distance from 52-week high-65.55%-57.64%
Analyst consensusbuynone
Avg. price target upside+305.10%+137.98%
Average volume352.88K23.10K
Shares outstanding62.84M95.13M
Employees179620
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About DBV Technologies S.A.

DBVT stock →

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees

About Valneva

VALN stock →

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees

DBVT vs VALN FAQ

Which is bigger, DBV Technologies S.A. or Valneva?

DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $566.82M compared with $490.86M for Valneva (VALN).

Which stock has performed better over the past year, DBVT or VALN?

DBVT returned -34.40% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.

Are DBV Technologies S.A. and Valneva in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons